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Synthesis and anticancer activity of silver(I)-N-
heterocyclic carbene complexes derived from the 
natural xanthine products caffeine, theophylline and 
theobromine 
Heba A. Mohamed,a Benjamin R. M. Lake,a Thomas Laing,b Roger M. Phillips*c 
and Charlotte E. Willans*a  
A new library of silver(I)-N-heterocyclic carbene complexes prepared from the natural 
products caffeine, theophylline and theobromine is reported. The complexes have been fully 
characterised using a combination of NMR spectroscopy, mass spectrometry, elemental 
analysis and X-ray diffraction analysis. Furthermore, the hydrophobicity of the complexes 
has been measured. The silver(I)-N-heterocyclic carbenes have been evaluated for their 
antiproliferative properties against a range of cancer cell lines of different histological types,  
and compared to cisplatin. The data shows different profiles of response when compared to 
cisplatin in the same panel of cells, indicating a different mechanism of action. Furthermore, 
it appears that the steric effect of the ligand and the hydrophobicity  of the complex both play 
a role in the chemosensitivity of these compounds, with greater steric bulk and greater 
hydrophilicity delivering higher cytotoxicity.  
 
Introduction 
Since their isolation in 1991,1 N-heterocyclic carbenes (NHCs) 
have become ubiquitous in organometallic chemistry, 
particularly in the field of catalysis.2-5 In more recent years, 
metal-NHCs have shown promise as antimicrobial (silver-
NHCs) and as antitumour (palladium-, copper-, silver- and 
gold-NHCs) agents.6-11 The antimicrobial properties of silver 
have been exploited for centuries, with silver now being 
incorporated into several materials such as wound dressings, 
creams, deodorants and even clothing. The efficacy of a silver-
based antibacterial compound appears to be linked to its 
bioavailability and  prolonged release of silver over a long 
period of time to prevent reinfection.12 The release rate is 
linked to the ancillary ligand and, DV1+&VDUHVWURQJı-donors, 
silver-NHCs can have a slow silver release rate. In addition to 
antimicrobial activity, several studies have demonstrated that 
silver-NHCs have a potential future in the field of cancer 
chemotherapy.13-16 
 Although platinum-based drugs such as cisplatin have been 
pivotal in the fight against cancer,17 severe side-effects and the 
development of drug resistance necessitate the need for new 
organometallic anticancer drugs. As silver is thought to have 
relatively low toxicity and is already used widely in 
biomedicine, it is a judicious choice of metal to study in cancer 
chemotherapy. However, it is imperative that the material 
(delivery agent) surrounding the silver also has a low toxicity 
profile. Xanthine derivatives (Figure 1) are natural products and 
are often found in beverages and foods such as coffee and 
chocolate. As xanthine derivatives contain an imidazole ring, 
these are potential precursors to NHCs. Due to the low toxicity 
and high versatility of these compounds, they are ideal to study 
in combination with silver as potential chemotherapeutic 
compounds. Furthermore, these compounds have themselves 
been used medicinally and have potential chemotherapeutic 
effects.18 Youngs and co-workers have previously prepared a 
silver(I)-NHC complex starting from caffeine, which was found 
to be active against resistant respiratory pathogens.19 The same 
group also added a hydroxyethyl group to the backbone of the 
NHC, with the silver(I) complex of this ligand being effective 
against a variety of cystic fibrosis relevant pathogens.20 
Caffeine-based NHC complexes of gold(I) have recently been 
reported and their biological properties investigated.21 Herein, 
we report the synthesis of a family of xanthine-derived 
imidazolium salts, prepared from caffeine, theophylline and 
theobromine. Silver(I)-NHC complexes were prepared from the 
imidazolium salt precursors and evaluated against eight cancer 
cell lines. 
ARTICLE Journal Name 
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 2012 
 
Fig. 1  Xanthine and naturally occurring derivatives of xanthine. 
Results and Discussion 
Imidazolium salts 2a-2e were prepared from either caffeine, 
theophylline or theobromine (Scheme 1). Methylation of 
caffeine to yield the corresponding imidazolium salt 2a is 
achieved through reaction with methyl iodide in DMF at 
reflux.19 Due to the volatility of methyl iodide, we found it 
necessary to use a large excess (20 equivalents) and heat in a 
closed system. We found that dimethyl sulfate and methyl 
tosylate could also be used as methylating agents to give similar 
product yields of the corresponding imidazolium methyl sulfate 
or tosylate salts (>70%). However, reaction of caffeine with 
other alkylating agents (benzyl bromide, 1-iodobutane) under 
the same conditions did not result in formation of an 
imidazolium salt, presumably due to the relatively low basicity 
of the nitrogen atom of the caffeine. Therefore, theophylline 
was employed as the precursor to initially add an alternative 
alkyl group, followed by methylation using methyl iodide. 
Imidazole compounds 1b and 1c were synthesised through 
reaction of benzyl bromide or 1-iodobutane with theophylline 
in acetonitrile at reflux, in the presence of a base (K2CO3). 
Imidazole compound 1d required an Ullmann-type coupling 
reaction, in which theophylline was reacted with aryl iodide 
using a copper catalyst (CuI, isobutyrylcyclohexanone, 
Cs2CO3). Imidazolium salts 2b-2d were then prepared by 
reaction of the appropriate imidazole with methyl iodide in 
DMF at reflux, again in a closed system. A hydroxyethyl 
functionality was added to the ligand architecture by reaction of 
theobromine with 2-iodoethanol in DMF at reflux, in the 
presence of a base (Cs2CO3), to give imidazole compound 1e.20 
This was subsequently reacted with methyl iodide under the 
same reaction conditions as previously described, to give 
imidazolium salt 2e.  
 
Scheme 1  Synthesis of imidazolium salts 2a-2e starting from caffeine, 
theophylline or theobromine. 
Imidazolium salts 2a-2e were fully characterised, and solid-
state structures were obtained for imidazolium salts 2b-2d (see 
Supporting Information). In each case, the backbone 
pyrimidinone of the imidazolium salt twists slightly out of the 
plane as defined by the N(1)-C(2)-N(4) bond. This twisting is 
most pronounced in imidazolium salt 2d, with a C(9)-N(4)-
C(7)-O(2) torsion angle of 9.19 ° (analogous torsion angles in 
2b and 2c are < 1 °). The greater degree of twisting in 2d 
presumably arises due to the steric constraints imposed by the 
phenyl N-substituent. 
 Reaction of imidazolium salts 2a-2e with AgOAc at room 
temperature resulted in formation of complexes of the type 
Ag(NHC)OAc 3a-3e (Scheme 2). Complex 2a was synthesised 
in methanol as previously reported.19 We found it necessary to 
use 1:1 mixtures of either methanol/dichloromethane (with 
ligand precursors 2b, 2c and 2e) or methanol/acetonitrile (with 
ligand precursor 2d) to aid solubility of the imidazolium salts 
for the syntheses of complexes 3b-3e.  
 
Scheme 2  Synthesis of silver-NHC complexes 3a-3e 
Silver(I)-NHC complexes 3a-3e were fully characterised, and 
solid-state structures were obtained for complexes 3b-3d 
(Figure 2). In all three cases the geometry around the silver 
atom deviates from linearity, with C(2)-Ag(1)-O(3) bond angles 
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of 168.6-171.6° (Table 1). This deviation is consistent with the 
structure of complex 2a, which has previously been reported in 
the literature.19 The silver-carbene bond lengths for complexes 
3c (2.078(3) Å) and 3d (2.068(4) Å) are similar to those for 
complexes 3a (2.067(3) Å) and 3e (2.072(4) Å) which have 
previously been reported. The silver-carbene bond length in 
complex 3b (2.052(7) Å), however, is shorter than those 
observed in other similar complexes. This is likely due to the 
flexibility of the benzyl substituent, hence lower steric effect, 
allowing closer interaction between the carbenic centre and the 
silver ion. The nbutyl substituent in complex 3c is not expected 
to impart any significant steric constraints on the carbenic 
carbon. However, a possible argentophilic interaction of 
approximately 3.2 Å may cause the lengthening of the silver-
carbene bond in the solid-state structure of this complex. 
 
 
 
Fig. 2  Molecular structures of silver(I)-NHC complexes 3b-3d. Hydrogen atoms 
have been omitted for clarity and ellipsoids are shown at 50 % probability.  
Bond lengths (Å) 
and angles (°) 
3b 3c 3d 
Ag(1)-C(2) 2.052(7) 2.078(3) 2.068(4) 
Ag(1)-O(3) 2.120(5) 2.1042(19) 2.111(3) 
C(2)-Ag(1)-O(3) 171.4(2) 168.72(9) 168.94(11) 
N(1)-C(2)-N(4) 105.2(5) 105.46(18) 105.6(3) 
Ag(1)-Ag(2) - 3.1931(3) - 
Table 1  Selected bond lengths (Å) and angles (°) for silver(I)-NHC 
complexes 3b-3d. 
The in vitro cytotoxicity of silver(I)-NHC complexes 3a-3e was 
determined using MTT-based assays involving a 96 hour drug-
exposure period. Compounds were tested for their activity 
against A375 (malignant melanoma), HCT116 (colorectal 
carcinoma), HT-29 (colorectal adenocarcinoma), LN229 
(glioblastoma), Panc-1 (pancreatic carcinoma), SiHa (grade II, 
squamous cell carcinoma cervix), U-87 MG (glioblastoma) and 
U-251 (glioblastoma). The results are summarised in Table 2 
and Figure 3. Complexes 3a-3e exhibit moderate cytotoxicity 
against the cell lines tested, with IC50 values being in the 
micromolar range.  
 The profiles of response in this panel of cells is different to 
that for cisplatin, indicating a different mechanism of action for 
silver(I)-NHC complexes. The most cytotoxic silver complex in 
general across these cell-lines is 3d (see Supporting 
Information), in which the NHC ligand bears an N-phenyl 
substituent. The sterically encumbering phenyl group is likely 
to exert a stabilising effect on the silver-NHC bond, which may 
lead to a slower silver release rate and enhanced cytotoxicity 
profile. It is apparent that addition of a hydroxyethyl group to 
the backbone of the ligand improves activity, with complex 3e 
being on average 2-fold more cytotoxic than complex 3a. This 
is presumably due to the solubility of the complex, and its 
ability to cross the cell membrane. 
3b 
3c 
3d 
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Cell 
Line 
3a 3b 3c 3d 3e cisplatin 
A357 34.5 
±3.8 
21.4 
±7.5 
27.4 
±3.9 
11.5 
±5.3 
12.4 
±1.3 
1.2  
±0.3 
HCT116 26.7 
±9.9 
29.6 
±3.5 
22.4 
±4.8 
19.5 
±2.3 
19.0 
±5.1 
2.4  
±0.3 
HT-29 41.8 
±9.8 
29.9 
±16.5 
28.5 
±2.0 
21.4 
±6.5 
20.7 
±1.5 
0.6  
±0.1 
LN229 29.2 
±12.8 
18.4 
±12.0 
46.5 
±9.8 
11.2 
±1.5 
7.4 
±1.8 
0.7  
±0.5 
Panc-1 31.7 
±2.8 
29.7 
±8.2 
16.9 
±1.1 
7.6 
±3.2 
23.5 
±5.9 
2.6  
±0.9 
SiHa 21.9 
±3.8 
15.3 
±2.6 
16.4 
±0.5 
13.1 
±3.7 
14.0 
±2.2 
0.9  
±0.3 
U87MG 33.7 
±1.4 
22.8 
±5.1 
14.0 
±4.3 
17.6 
±4.5 
22.1 
±8.1 
0.9  
±0.4 
U-251 54.8 
±15.7 
26.7 
±8.8 
51.4 
±17.8 
14.2 
±2.5 
29.6 
±5.1 
1.0  
±0.6 
Table 2  Response of eight cell lines to silver(I)-NHC complexes 3a-3e and 
cisplatin. Values presented are IC50 µM ± SD (in parentheses) for three 
independent experiments. 
 
Fig. 3  Response of eight cell lines to silver(I)-NHC complexes 3a-3e and cisplatin. 
Values presented are IC50 (µM) ± SD for three independent experiments. The 
presentation of results is based on the sensitivity of cells to cisplatin with the 
most sensitive line on the far left whereas the most resistant line is on the far 
right. If the test compounds have a similar mechanism of action to cisplatin, 
similar patterns of chemosensitivity would be expected. 
As a means to assess the potential of complexes 3a-3e to enter a 
cell membrane,22 the hydrophobicity (Log P) of the five 
complexes was measured. Accurate amounts of each compound 
were dissolved in octanol-saturated water, with an equal 
amount of water-saturated octanol being layered on top. This 
was placed in the vibrax machine for 4 hours at 500 gmin-1. The 
layers were separated and the water-saturated octanol layer was 
analysed using UV-vis spectroscopy, with an average of at least 
six runs being taken. The results are summarised in Table 3 and 
S9 in the Supporting Information, with the complexes ranging 
from hydrophilic (-1.96) to hydrophobic (0.56). Cisplatin, with 
a Log P value of -2.36, is more hydrophilic than any of the 
silver(I)-NHC complexes tested. Complex 3e, like cisplatin, is 
hydrophilic, with the other complexes being more hydrophobic. 
Hydrophilicity is likely to lead to improved penetration of the 
cell membrane by complex 3e, hence its increased cytotoxicity 
when compared to complex 3a. It is clear, however, that 
hydrophobicity / hydrophilicity is not the single most important 
factor when considering the effect of these types of complexes 
against cancer cells. Though complex 3d is more hydrophobic 
than complex 3a, 3d is on average over 2-fold more cytotoxic 
than 3a. This indicates that a combination of both steric and 
solubility factors should be taken into account when designing 
new NHC ligands for study in chemotherapeutic applications. 
Complex Log P ± SD 
Cisplatin -2.36 0.01 
3a -0.01 0.03 
3b 0.53 0.02 
3c 0.56 0.07 
3d 0.1512 0.05 
3e -1.96 0.06 
Table 3  Log P values for complexes 3a-3e 
Conclusion 
Synthetic procedures have been developed for the preparation 
of imidazolium salts from caffeine, theophylline and 
theobromine. Due to the relatively low basicity of the nitrogen 
donor in caffeine, it was found necessary to initially add 
varying substituents to theophylline. Following this, 
methylation was achieved through heating the imidazole 
compounds with a large excess of methyl iodide in a closed 
system. The imidazolium salts were reacted with silver acetate 
to prepare silver(I)-NHC complexes of the type Ag(NHC)OAc. 
These were fully characterised and the solid-state structures 
determined through the use of X-ray diffraction techniques. The 
antiproliferative activities of the silver complexes were 
examined against eight cancer cell lines, and compared to 
cisplatin. Whilst these complexes were less active than cisplatin 
against the cell lines tested, their IC50 values were in the 
micromolar range. The hydrophobicity of each complex was 
also measured to assess their potential to cross the cell 
membrane. Upon comparing the chemosensitivity data for each 
complex and considering their hydrophobicity / hydrophilicity 
profiles, it is evident that a combination of both steric effects of 
the ligand and solubility of the silver complex play a role in 
their activity against cancer cells. Sterically bulky N-
substituents on the ligand may result in a slower release rate of 
silver from the complex, leading to increased cytotoxicity, 
whilst a more hydrophilic complex is likely to have increased 
penetration through the cell membrane. 
Experimental 
General considerations 
Manipulations were performed under an atmosphere of dry 
nitrogen by means of standard Schlenk line techniques. The gas 
was dried by passing through a twin-column drying apparatus 
containing molecular sieves (4Å) and P2O5. Anhydrous solvents 
were prepared by passing the solvent over activated alumina to 
remove water, copper catalyst to remove oxygen and molecular 
sieves to remove any remaining water, via the Dow-Grubbs 
solvent system. 1H and 13C{1H} NMR spectra were recorded on 
a Bruker DPX300 spectrometer. The values of chemical shifts 
are given in ppm and values for coupling constants (J) in Hz. 
Mass spectra were collected on a Bruker Daltonics (micro 
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TOF) instrument operating in the electrospray mode. 
Microanalyses were performed using a Carlo Erba Elemental 
Analyser MOD 1106 spectrometer. X-ray diffraction data were 
collected on an Agilent SuperNova diffractometer fitted with an 
Atlas CCD detector with Mo-.ĮUDGLDWLRQȜ cRU
&X.ĮUDGLDWLRQȜ = 1.5418 Å). Crystals were mounted under 
oil on glass or nylon fibres. Data sets were corrected for 
absorption using a multiscan method, and the structures were 
solved by direct methods using SHELXS-97 and refined by 
full-matrix least squares on F2 using ShelXL-97, interfaced 
through the program X-Seed. Molecular graphics for all 
structures were generated using POV-RAY in the X-Seed 
program. Imidazolium salts 2a and 2e and silver(I)-NHC 
complexes 3a and 3e were prepared using slightly modified 
literature procedures.19, 20 
Synthesis of 9-benzyl-1,3,5-trimethylxanthine (1b) 
Theophylline (5.0 g, 27.8 mmol) was dissolved in acetonitrile 
(80 mL) and benzyl bromide (16.5 mL, 138.7 mmol) and 
potassium carbonate (4.25 g, 30.8 mmol) were added. The 
mixture was heated to reflux for 24 hours.  The mixture was 
filtered and washed with acetonitrile. The filtrate was dried in 
vacuo to yield the product as a white solid. Yield: 6.1 g  (81%). 
1H NMR (300 MHz, CDCl3) į: 7.58 (s, 1H, NCHN), 7.43-7.32 
(m, 5H, aromatic), 5.52 (s, 2H, CH2), 3.60 (s, 3H, CH3), 3.13 (s, 
3H, CH3). 13C{1H} NMR (75 MHz, CDCl3) į: 153.4 (C=O), 
150.1 (C=O), 139.4 (C), 136.1 (NCHN),  133.6 (C), 127.2, 
126.9, 126.6 (CH), 105.1 (C), 48.3 (CH3), 31.8 (CH3), 27.9 
(CH2). HRMS (ESI+): Calcd for C14H15N4O2 [M+H]+: 
271.1195. Found: 271.1188. Anal. Calcd for 
C14H14N4O2·1/3Et2O: C, 62.43; H, 5.92; N, 18.99. Found: C, 
63.00; H, 5.45; N, 19.40. 
Synthesis of 9-butyl-1,3,5-trimethylxanthine (1c) 
Theophylline (5.0 g, 27.8 mmol) was dissolved in acetonitrile 
(70 mL), and butyl iodide (12.0 mL, 105.5 mmol) and 
potassium carbonate (4.25 g, 30.8 mmol) were added. The 
mixture was heated to reflux for 48 hours, filtered, and washed 
with acetonitrile. The filtrate was dried in vacuo to yield the 
product as a white solid. Yield: 4.7 g (74%) 1H NMR (300 
MHz, d6-'062įV+1&+1WJ = 7.22 Hz, 
2H, CH2), 3.42 (s, 3H, CH3), 3.19 (s, 3H, CH3), 1.74 (quin, J = 
7.22 Hz, 2H, CH2), 1.24 (sext, J = 7.22 Hz, 2H, CH2), 0.85 (t, J 
= 7.22 Hz, 3H, CH3). 13C{1H} NMR (75 MHz, CDCl3į 
(C=O), 151.7 (C=O), 148.9 (C), 140.8 (NCHN), 106.9 (C), 47.0 
(CH2), 32.8 (CH2), 29.7 (CH2), 27.9 (CH3), 19.5(CH3), 13.4 
(CH3). HRMS (ESI+): Calcd for C11H17N4O2 [M+H]+: 
237.1351. Found: 237.1345. Anal. Calcd for C11H16N4O2: C, 
55.92; H, 6.83; N, 23.71. Found: C, 55.40; H, 6.85; N, 23.30. 
Synthesis of 9-phenyl-1,3,5-trimethylxanthine (1d) 
Theophylline (4.0 g, 22.2 mmol), copper(I) iodide (1.9 g, 10.0 
mmol), 2-isobutyrylcyclohexanone (2.2 mL, 13.1 mmol) and 
caesium carbonate (6.52 g, 20.0 mmol) were placed in a 
Schlenk flask and degassed. Anhydrous dimethylsulfoxide (17 
mL) and iodobenzene (3.5 mL, 31.3 mmol) were added to the 
flask. The mixture was heated at 130 °C for 24 hours. The dark 
brown solution obtained was dissolved in dichloromethane and 
extracted with water three times. The aqueous layers were 
combined and washed with dichloromethane three times. All of 
the organic layers were combined and dried in vacuo to give a 
dark brown solid. Recrystallisation from dichloromethane / 
diethyl ether yielded the product as a white solid. To ensure 
complete removal of the copper, the solid was dissolved in 
dichloromethane and a saturated solution of EDTA was added. 
The organic layer was extracted and dried in vacuo to give a 
white solid. Yield: 1.78 g (34%). 1H NMR (300 MHz, d6-
'062įV+1&+1-7.14 (m, J = 7.54 Hz, 5H, 
aromatic), 3.46 (s, 3H, CH3), 3.18 (s, 3H, CH3). 13C{1H} NMR 
(75 MHz, d6-'062į 153.7 (C=O), 150.9 (C=O), 149.2 (C), 
142.7 (NCHN), 134.8 (C), 128.9 (CH), 128.5 (CH), 125.1 
(CH), 106.1 (C), 29.6 (CH3), 27.8 (CH3). HRMS (ESI+): Calcd 
for C13H13N4O2 [M+H]+: 257.1039. Found: 257.1031. Anal. 
Calcd for C13H12N4O2: C, 60.93; H, 4.72; N, 21.86. Found: C, 
60.60; H, 4.85; N, 21.80. 
Synthesis of 9-benzyl-1,3,5-trimethylxanthinium iodide (2b) 
Imidazole 1b (2.6 g, 9.6 mmol) was dissolved in 
dimethylformamide (3 mL) in an ampoule, and methyl iodide 
(11.9 mL, 191 mmol) was added. The mixture was heated at 70 
°C for 24 hours in a closed system resulting in a clear red 
solution. Excess diethyl ether was added to the flask to 
precipitate an orange powder which was filtered. Further 
recrystallisation using dichloromethane / diethyl ether and 
acetonitrile / diethyl ether resulted in the product as a yellow 
solid. Yield: 0.8 g (20%). 1H NMR (300 MHz, DMSO-d6 į 
9.49 (s, 1H, NCHN), 7.46-7.37 (m, 5H, aromatic), 5.75 (s, 2H, 
CH2), 4,16 (s, 3H, CH3),  3.73 (s, 3H, CH3), 3.26 (s, 3H, CH3). 
13C{1H} NMR (75 MHz, DMSO-d6 į 153.1 (C=O), 150.1 
(C=O), 139.8 (C), 139.4 (NCHN), 134.4 (C), 128.8 (CH), 128.7 
(CH), 128.2 (CH), 106.9 (C), 51.1 (CH3), 37.2 (CH3), 31.3 
(CH3), 28.4 (CH2). HRMS (ESI+): Calcd for C30H33N8O4 [2M-
H]+: 569.2614. Found: 569.2619. Calcd for C15H16N4O2Na [M-
H+Na]+: 307.117096. Found: 307.116546. Anal. Calcd for 
C15H17IN4O2·¼Et2O: C, 44.61; H, 4.56; N, 13.01. Found: C, 
44.80; H, 4.30; N, 12.70. MP: 200.2-203.4 °C. 
Synthesis of 9-butyl-1,3,5-trimethylxanthinium iodide (2c) 
Imidazole 1c (4.5 g, 19.1 mmol), methyl iodide (23.7 mL, 381 
mmol) and dimethylformamide (10 mL) were added to an 
ampoule and heated at 70 °C for 24 hours in a closed system. 
Excess diethyl ether was added to the solution to precipitate a 
yellow solid. The solid was filtered and recrystallised from 
dichloromethane / diethyl ether, and dried in vacuo to yield the 
product as a bright yellow solid. Yield: 6.3 g (87%). 1H NMR 
(300 MHz, d6-'062įV+1&+1W J = 7.25 
Hz, 2H, CH2), 4.16 (s, 3H, CH3), 3.76 (s, 3H, CH3), 3.26 (s, 3H, 
CH3), 1.82 (quin, J = 7.25 Hz, 2H, CH2), 1.31 (sext, J = 7.25 
Hz, 2H, CH2), 0.91 (t, J = 7.25 Hz, 3H, CH3). 1H NMR (300 
MHz, CDCl3įV+1&+1W J = 7.20 Hz, 2H, 
CH2), 4.48 (s, 3H, CH3), 3.87 (s, 3H, CH3), 3.40 (s, 3H, CH3), 
1.99 (quin, J = 7.20 Hz, 2H, CH2), 1.45 (sext, J = 7.20 Hz, 2H, 
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CH2), 0.98 (t, J = 7.20 Hz, 3H, CH3). 13C{1H}  NMR (75 MHz, 
CDCl3 į 153.1 (C=O), 149.9 (C=O), 139.5 (C), 138.6 
(NCHN), 107.8 (C), 49.7 (CH3), 38.9 (CH2), 32.3 (CH2), 32.1 
(CH3), 28.7 (CH2), 19.4 (CH3), 13.3 (CH3). HRMS (ESI+): 
Calcd for C12H19N4O2 [M-I]+: 251.1508. Found: 251.1589. 
Anal. Calcd for C12H19IN4O2: C, 38.11; H, 5.06; N, 14.81. 
Found: C, 37.80; H, 5.00; N, 14.60. M.P: 142.4-144.7 °C. 
Synthesis of 9-phenyl-1,3,5-trimethylxanthinium iodide (2d) 
Imidazole 1d (0.2 g, 0.78 mmol), methyl iodide (0.91 mL, 14.6 
mmol) and dimethylformamide (4 mL) were added in an 
ampoule. The mixture was heated at 70 °C for 24 hours in a 
closed system. Excess diethyl ether was added to the resulting 
orange solution to precipitate the product as a yellow solid that 
was filtered and dried in vacuo. Yield: 0.15 g (97%). 1H NMR 
(300 MHz, d6-'062 į  V + 1&+1  EURDG V
5H, aromatic), 4.25 (s, 3H, CH3), 3.82 (s, 3H, CH3), 3.40 (s, 
3H, CH3). 13C{1H} NMR (75 MHz, d6-'062į (C=O), 
151.9 (C=O), 140.3 (C), 139.8 (NCHN), 132.7 (C), 130.7 (CH), 
129.3 (CH), 125.8 (CH), 109.5(C),  35.7 (CH3), 28.5 (CH3), 
26.3 (CH3). HRMS (ESI+): Calcd for C14H15N4O2 [M-I]+: 
271.1190. Found: 271.1188. Anal. Calcd for 
C14H15IN4O2·3H2O: C, 37.18; H, 4.68; N, 12.39. Found: C, 
36.80; H, 4.20; N, 12.20. M.P: 168.1-169.4 °C. 
Synthesis of 9-benzyl-1,3,5-trimethylxanthine-8-ylidene silver 
acetate (3b) 
Imidazolium salt 2b (0.25 g, 0.61 mmol) was added to silver 
acetate (0.2 g, 1.2 mmol) in a mixture of anhydrous 
dichloromethane (5 mL) and methanol (5 mL). The mixture 
was stirred at room temperature for two hours in the dark. The 
mixture was filtered, with the solid being washed with 
dichloromethane, and the filtrate was dried in vacuo to give the 
product as a white solid which was recrystallized from 
dichloromethane / pentane. Yield: 0.3 g (40%). 1H NMR (300 
MHz, CDCl3 į 9 (m, 2H, aromatic), 7.31 (m, 3H, 
aromatic), 5.66 (s, 2H, CH2), 4.21 (s, 3H, CH3), 3.79 (s, 3H, 
CH3), 3.38 (s, 3H, CH3), 2.05 (s, 3H, CH3). 13C{1H} NMR (75 
MHz, CDCl3 į $J-C not observed, 178.2 (C=O), 153.2 
(C=O), 150.7 (C=O), 140.4 (C), 135.4 (C), 129.1 (CH), 128.8 
(CH), 128.5 (CH), 109.3 (C), 54.4 (CH3), 40.1 (CH3), 32.1 
(CH3), 28.9 (CH2), 22.4 (CH3). HRMS (ESI+): Calcd for 
C30H32N8O4Ag [Ag(NHC)2]+: 675.1597. Found: 675.1616. 
Anal. Calcd for C17H19AgN4O4: C, 45.25; H, 4.24; N, 12.42. 
Found: C, 45.30; H, 4.20, N, 12.20. 
Synthesis of 9-butyl-1,3,5-trimethylxanthine-8-ylidene silver 
acetate (3c) 
Imidazolium salt 2c (0.10 g, 0.26 mmol) was dissolved in 
anhydrous methanol (5 mL) and dichloromethane (5 mL) and 
silver acetate (0.09 g, 0.54 mmol) were added. The mixture was 
stirred for two hours in the dark. The mixture was filtered, with 
the solid being washed with dichloromethane, and the filtrate 
was dried in vacuo to yield a white sticky solid. 
Recrystallisation from dichloromethane / diethyl ether gave the 
product as a white solid which was further dried in vacuo. 
Yield: 0.06 g (55%). 1H NMR (300 MHz, CDCl3įW J = 
7.35 Hz, 2H, CH2), 4.22 (s, 3H, CH3), 3.80 (s, 3H, CH3), 3.38 
(s, 3H, CH3), 2.00 (s, 3H, CH3), 1.79 (quin, J = 7.35 Hz, 2H, 
CH2), 1.37 (sext, J = 7.35 Hz, 2H, CH2), 0.92 (t, J = 7.35 Hz, 
3H, CH3). 13C{1H} NMR (75 MHz, d6-'062 į Ag-C and 
C=O (acetate) not observed, 153.0 (C=O), 150.6 (C=O), 140.8 
(C), 108.3 (C), 50.3 (CH3), 39.4 (CH2), 33.0 (CH3), 31.6 (CH3), 
28.3 (CH2), 19.10 (CH2), 13.6 (CH3). HRMS (ESI+): m/z Calcd 
for C24H36AgN8O4 [Ag(NHC)2]+: 608.1910. Found: 608.1939. 
Anal. Calcd for C14H21AgN4O4: C, 40.30; H, 5.07; N, 13.43. 
Found: C, 39.90; H, 5.30, N, 13.10. 
Synthesis of 9-phenyl-1,3,5-trimethylxanthine-8-ylidene silver 
acetate (3d) 
Imidazolium salt 2d (0.15g, 0.38 mmol) was dissolved in 
anhydrous acetonitrile (5 mL), and methanol (5 mL) and silver 
acetate (0.125 g, 0.75 mmol) were added. The mixture was 
stirred at room temperature for two hours in the dark. The 
mixture was filtered and the solvent removed from the filtrate 
in vacuo to give the product as a white solid. Yield: 0.115 g 
(69.1%). 1H NMR (300 MHz, d6-'062į3 (broad s, 5H, 
aromatic), 4.27 (s, 3H, CH3), 3.80 (s, 3H, CH3), 3.19 (s, 3H, 
CH3), 1.78 (s, 3H, CH3). 13C{1H} NMR (75 MHz, d6-'062į
186.1 (Ag-C), 175.5 (C=O), 152.1 (C=O), 150.5 (C=O), 141.1 
(C), 137.9 (C), 129.3 (CH), 128.9 (CH), 126.6 (CH), 109.3 (C), 
31.7 (CH3), 28.3 (CH3), 23.2 (CH3). HRMS (ESI+): m/z Calcd 
for C28H28AgN8O4 [Ag(NHC)2]+: 647.1284. Found: 647.1297. 
Anal. Calcd for C16H17AgN4O4: C, 43.96; H, 3.92; N, 12.82. 
Found: C, 44.70; H, 4.40, N, 12.60. 
Cytotoxicity studies 
In vitro cell tests were performed at the Institute of Cancer 
Therapeutics, Bradford. Cells were incubated in 96-well plates, 
at 2 x 103 cells per well in 200 µL of growth media (RPMI 
1640 supplemented with 10 % foetal calf serum, sodium 
pyruvate (1mM) and L-glutamine (2mM)). Cells were 
incubated for 24 hours at 37 ºC in an atmosphere of 5 % CO2 
prior to drug exposure. Silver compounds and cisplatin were 
dissolved in dimethylsulfoxide at a concentration of 25 mM and 
diluted with medium to obtain drug solutions ranging from 25 
µM to 0.049 µM. The final dimethylsulfoxide concentration 
was 0.1% (v/v) which is non-toxic to cells. Drug solutions were 
applied to cells and incubated for 96 hours at 37 ºC in an 
atmosphere of 5 % CO2. The solutions were removed from the 
wells and fresh medium added to each well along with 20 µL 
MTT (5mg / mL), and incubated for 4 hours at 37 ºC in an 
atmosphere of 5 % CO2. The solutions were removed and 150 
µL dimethylsulfoxide was added to each well to dissolve the 
purple formazan crystals. A plate reader was used to measure 
the absorbance at 540 nm. Lanes containing medium only, and 
cells in medium only (no drug), were used as blanks for the 
spectrophotometer and 100 % cell survival respectively. Cell 
survival was determined as the true absorbance of treated cells 
divided by the true absorbance of controls and expressed as a 
percentage. The concentration required to kill 50 % of cells 
(IC50) was determined from plots of % survival against drug 
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concentration. Each experiment was repeated 3 times and a 
mean value obtained. 
Hydrophobicity 
Equal volumes of octanol and NaCl-saturated water were 
stirred at room temperature for 24 hours, and separated to give 
octanol-saturated water and water-saturated octanol. Five 
standard concentrations (5, 10, 20, 40 and 60 µM) of the 
complexes were prepared from the octanol-saturated water. 
Analysis using UV / vis spectroscopy was used to obtain a 
calibration curve of absorbance vs. concentration for each 
complex at its maximum absorbance. Accurate amounts of the 
complexes were dissolved in the octanol-saturated water (25 
mL) to make up a concentration of 50 µM. 3 mL of octanol-
saturated water containing the complex was placed in a 
centrifuge tube and 3 mL of water-saturated octanol was 
layered on top. Six samples prepared in this manner were 
shaken for 4 hours using a vibrax machine at 500 gmin-1. The 
layers were separated and the octanol-saturated water layer was 
retained for analysis using UV / vis spectroscopy. The average 
concentration of the six runs was calculated using the 
calibration graph and maximum absorbance for each complex. 
Subtraction of the average concentration obtained from the 
concentration of an unshaken sample in octanol-saturated water 
gave the final [C]org. The [C]org and [C]aq were used to 
determine the partition coefficient Log P. 
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